Coya Therapeutics Inc. Common Stock (COYA)
Stock · NASDAQ · Health Care
$4.28as of 10/16/2026
Price chart
Active signals
COYA Signal Track Record
How signals performed across all stocks →What COYA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +0.6% | 53% | September 8, 2026 |
| Bollinger Band Breakout | 17 | -6.5% | 41% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -8.1% | 31% | October 1, 2026 |
| Bollinger Band Breakdown | 13 | +4.4% | 62% | March 30, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since October 16, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration inte…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- www.coyatherapeutics.com/
Fundamentals
- 1-day range
- $4.16$4.39
- Market cap
- $107.43M
- P/E (trailing)
- —
- P/E (forward)
- -2.21
- EPS (trailing)
- $-1.07
- Dividend yield
- —
- Beta
- 0.59
- Avg. volume
- 140.7K
How Coya Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Coya Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- COYACoya Therapeutics Inc. Common Stock$4.25▼ 2.07%Market cap $107.43MP/E —$3.71$7.75
- RFLRafael Holdings Inc. Class B Common Stock$1.39▼ 5.44%Market cap $105.04MP/E —$1.12$3.96
- PLYXPolaryx Therapeutics Inc. Common Stock$1.88▼ 3.59%Market cap $110.66MP/E —$1.85$48.91
- NRXPNRX Pharmaceuticals Inc. Common Stock$2.6▼ 4.06%Market cap $111.95MP/E —$1.62$5.06
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
- ZYBTZhengye Biotechnology Holding Limited Class A Ordinary Shares$1.4▼ 6.67%Market cap $99.05MP/E —$0.6155$8.01
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COYA Coya Therapeutics Inc. Common Stock | $107.43M | — | $4.25 | ▼ 2.07% | $3.71$7.75 |
| RFL Rafael Holdings Inc. Class B Common Stock | $105.04M | — | $1.39 | ▼ 5.44% | $1.12$3.96 |
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $1.88 | ▼ 3.59% | $1.85$48.91 |
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $2.6 | ▼ 4.06% | $1.62$5.06 |
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
| ZYBT Zhengye Biotechnology Holding Limited Class A Ordinary Shares | $99.05M | — | $1.4 | ▼ 6.67% | $0.6155$8.01 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosisbenzinga · 10/14/2026
- Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSYahoo · 10/5/2026
- Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral SclerosisBenzinga · 10/5/2026
- BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price TargetBenzinga · 9/15/2026
- Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSYahoo · 9/15/2026
- Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302Benzinga · 9/15/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 8.05M
- Total value held
- $31.65M
- Institutional holders
- 54
- Unknown2.34M
- Unknown975.4K
- Unknown844.9K
- Unknown800.0K
- Unknown420.4K
- Unknown375.0K
- Unknown369.1K
- Unknown233.4K
- Unknown225.8K
- Unknown104.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial
Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.